옵션 체인은 다양한 행사가격과 만기일에 대한 HOOKIPA Pharma의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 HOOKIPA Pharma에 대한 시장 심리를 평가합니다..

HOOKIPA Pharma (NASDAQ:HOOK) 주식, 옵션 체인

HOOKIPA PHARMA INC

HOOKIPA Pharma

HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.

benzinga_deal_dispatch2

Government

Health Care

Retail Sales

Global

Startups

Small Business

AVGO

DKNG

HOOK

QCOM

SBGI

블록에 신규 등장 베라 브래들리(NASDAQ:VRA)의 매출이 감소했다. 이 핸드백 브랜드의 최대 주주인 Fund 1 Investments LLC는 이에 불만을 나타냈다. 12월 30일 이사회에 보낸 서한에서 공동 창립자인 바바라 브래들리 바엑가르드(Barbara Bradley Baekgaard)의 디자인을 &#34;상징적&#34;이고 &#34;수십 년간 혁신과 파괴의 대명사&#34;라고 언급했다.

딜 디스패치: 베라 브래들리는 명암이 혼재된 핸드백, 모델스의 전 CEO가 파티 시티를 탐색

HOOKIPA Pharma Inc

Hooker Furnishings Corporation - Common Stock

Hooker Furnishings Corp

Cantor Fitzgerald analyst Brett Knoblauch maintains HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Overweight and raises the price target from $5 to $5.5.

News

Price Target

Analyst Ratings

HIVE

Cantor Fitzgerald Maintains Overweight on HIVE Digital Technologies, Raises Price Target to $5.5

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457514-1&amp;h=3748747261&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced new patient-reported post-hoc data from the KINECT&#xAE;-HD study highlighting significant reductions in both cognitive and motor-related burdens among adults treated for Huntington's disease chorea with once-daily <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457514-1&amp;h=1598651954&amp;u=https%3A%2F%2Fwww.ingrezza.com%2Fhuntingtons-chorea&amp;a=INGREZZA%C2%AE+(valbenazine)+capsules">INGREZZA&#xAE; (valbenazine) capsules</a>. KINECT-HD is the first and only clinical study to demonstrate measurable changes in cognitive and motor disease burden with a vesicular monoamine transporter 2 inhibitor (INGREZZA) in patients treated for chorea. These analyses will be presented at the 2025 Advanced Therapeutics in Movement &amp; Related Disorders Congress hosted by the Parkinson &amp; Movement Disorder Alliance in Washington, D.C.

NBIX

Neurocrine Reports Post-Hoc Data Demonstrating Cognitive, Motor Disease Burden With INGREZZA In HD Chorea

William Blair analyst Ryan Merkel initiates coverage on James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) with a Outperform rating.

Initiation

William Blair Initiates Coverage On James Hardie Industries with Outperform Rating

Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Overweight and maintains $8 price target.

Reiteration

PRQR

Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target

Major U.S. corporations are increasingly adding Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to their balance sheets, raising concerns about potential market risks as the trend accelerates under <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46131815/trumps-crypto-advisor-david-sacks-says-july-will-be-a-big-month-says-president-supports-legislation-on-market-structure-and-stablecoins">President Donald Trump's administration</a>.
Companies like Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) are driving this surge, recently announcing plans to invest around $2.5 billion in Bitcoin through stock and debt sales.
Trump's pro-crypto stance has significantly reshaped the regulatory landscape, Politico <a href="https://www.politico.com/news/2025/06/27/trump-bitcoin-treasury-wall-street-warren-00423673">reported</a>.
His administration's rollback of enforcement actions and push for crypto-friendly legislation have emboldened corporate America to embrace digital assets more aggressively. 
According to Standard Chartered, more than 60 publicly traded companies globally now hold over 673,000 Bitcoin, valued at approximately $75 billion as of May's end. 
Trump Media, among the most notable participants, is allocating substantial capital to Bitcoin, with CEO Devin Nunes calling it "an apex instrument of financial freedom."
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46121954/retail-investors-can-now-trade-spacex-shares-heres-how">Retail Investors Can Now Trade SpaceX Shares: Here&#8217;s How</a>
Trump family members, including Eric Trump, have publicly championed Bitcoin adoption at recent industry events, reflecting a broader shift in sentiment where companies view Bitcoin as a viable treasury asset alongside traditional holdings like U.S. Treasuries.
Despite the enthusiasm, several lawmakers and experts are voicing caution. 
Senator Elizabeth Warren (D-Mass.) has warned that widespread corporate exposure to Bitcoin could amplify the economic fallout in the event of a future crypto crash, potentially leading to business failures and job losses across sectors.
Nic Carter, a partner at Castle Island Ventures, likened the current buildup of corporate Bitcoin holdings to &#8220;kindling&#8221; that could fuel a market collapse. 
Columbia University's Omid Malekan echoed the sentiment, pointing out the crypto industry's repeated cycles of overconfidence followed by painful corrections.
The practice, popularized by Michael Saylor's Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), has since been adopted by other firms like Japan's Metaplanet (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MTPLF#OTC">MTPLF</a>) and the Trump-backed American Bitcoin.
These companies raise capital at low cost through stock and debt markets and use the proceeds to buy Bitcoin, a strategy that has driven their stock prices higher.
However, critics like investor Jim Chanos argue that these gains are unsustainable. 
He believes the valuations of such firms could plummet if Bitcoin prices fall, warning that many of these companies are not adding meaningful value beyond buying Bitcoin itself.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46119440/why-did-this-uae-based-fund-just-purchase-100m-worth-of-trump-affiliated-wlfi-tokens">Why Did This UAE-Based Fund Just Purchase $100M Worth Of Trump-Affiliated WLFI Tokens?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Short Sellers

$BTC

MSTR

MTPLF

Corporate Bitcoin Buying Spree: Booming Strategy Or Ticking Financial Time Bomb?

WIIM

BURU

NUBURU shares are trading higher after the company said the regulatory approval process for its acquisition of Tekne SpA is progressing 'positively and in line with expectations.'

LAES

WKEY

WISeKey's Subsidiary WISeSat.Space Is On Target To Deploy 100-Satellite Constellation By 2027 In Cooperation With WISekey And SEALSQ

Regulations

NUBURU Says Regulatory Approval Process For Acquisition Of Tekne SpA Is 'progressing positively and in line with expectations'

Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Overweight and maintains $96 price target.

Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target

Stock Split

HSDT

Helius Medical Technologies Announces 1-For-50 Reverse Split Of Its Class A Common Stock

Offerings

OTRK

Ontrak Health Prices Public Offering Of 6,666,667 Shares And 26,666,668 Warrants At Combined Public Offering Price Of $0.60 Per Share And Accompanying Warrant; Gross Proceeds ~$4M

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients and a well-matched external control group. Collectively, the results demonstrate a 61% response rate and, compared to the matched external control, a three-fold improvement in overall survival. The submission also includes outcomes in over 130 TA-TMA patients treated with narsoplimab under Omeros' expanded access program.
Narsoplimab has been granted orphan drug designation by the EMA for treatment in hematopoietic stem cell transplant, enabling review of the MAA through the centralized procedure. This allows for a single marketing authorization to cover all EU member states and the European Economic Area countries of Iceland, Liechtenstein and Norway.
The review procedure begins in mid-July and will follow a standard review timeline. The Committee for Medicinal Products for Human Use (CHMP) will conduct the scientific assessment and will issue an opinion at the end of the review. This opinion is typically adopted by the European Commission, with a final decision expected in mid-2026.
The MAA submission follows the acceptance for review by the U.S. Food and Drug Administration (FDA) of the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of TA-TMA. The resubmission was assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025.

OMER

Omeros Submits MAA To EMA For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Market Outperform and maintains $8 price target.

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

CISO

CISO Global Files Renewal Of S-3 Shelf Registration, Reducing Total Shelf From $300M To $100M

Macro Economic Events

Econ #s

Economics

US PCE Price index (YoY) (May) +2.3% vs +2.3% Est.

USA Core PCE Price Index (MoM) (May) +0.2% vs +0.1% Est.

PCE Price Index MoM For For May 0.1% Vs 0.1% Expected

Macro Notification

General

Core PCE Price Index (YoY) (May) +2.7% vs +2.6% Est.

JMP Securities analyst Patrick Walravens reiterates Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Market Outperform and maintains $17 price target.

JMP Securities Reiterates Market Outperform on Sprinklr, Maintains $17 Price Target

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Market Outperform and maintains $86 price target.

CRSP

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

Press Releases

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Earnings

HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

Comments

HOOKIPA Pharma

HOOKIPA Pharma (HOOK) 옵션

HOOKIPA Pharma (NASDAQ:HOOK) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌